KIORA PHARMACEUTICALS INC
Public company- Headquarters
- ENCINITAS, California
- Ticker
- KPHMW
- CIK
- 0001372514
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Executive Vice President, Head of Clinical Development and Regulatory AffairsKeith Lane | Sep 8, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive appointment
Executive Vice President, Head of Clinical Development and Regulatory Affairs appointed: Keith Lane
Keith Lane was named Executive Vice President, Head of Clinical Development and Regulatory Affairs of KIORA PHARMACEUTICALS INC, effective September 8, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 8, 2026Role: Executive Vice President, Head of Clinical Development and Regulatory Affairs
Only one public record so far. We add events as soon as a new filing lands; watch KIORA PHARMACEUTICALS INC to get them in your digest.
Last verified Nov 8, 2026